We are live on ! Find out more
NRXPW

NRX Pharmaceuticals Warrant
NRXPW

Delisted

NRXPW was delisted on the 22nd of May, 2026.

Back to rankings

17 hedge funds and large institutions have $616K invested in NRX Pharmaceuticals Warrant in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

6% more funds holding

Funds holding: 16 → 17 (+1)

4% more capital invested

Capital invested by funds: $593K → $616K (+$23K)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
17
Holders Change
+1
Holders Change %
+6.25%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
2
Closed
1
Calls
$18K
Puts
–
Net Calls
+$18K
Net Calls Change
+$18K

Top Buyers

Rank Fund Capital Flow
1
BCM
Bluefin Capital Management
New York
+$25.6K
2
Walleye Trading
Walleye Trading
New York
+$3.53K
3
PC
Periscope Capital
Ontario, Canada
+$1.69K

Top Sellers

Rank Fund Capital Flow
1
KPF
K2 Principal Fund
Ontario, Canada
-$25.5K
2
BI
Bulldog Investors
New Jersey
-$5.65K
3
GCL
Glazer Capital LLC
New York
-$244
Name Holding Trade Value Shares
Change 		Change in
Stake
BFM
1
Boothbay Fund Management
New York
$353K – – –
PAMP
2
Polar Asset Management Partners
Ontario, Canada
$36K – – –
VAS
3
VR Advisory Services
Cayman Islands
$29K – – –
BI
4
Bulldog Investors
New Jersey
$22K -$5.65K -22,410 -16%
RCM
5
Rivernorth Capital Management
Florida
$22K – – –
WCMNY
6
Westchester Capital Management (New York)
New York
$22K – – –
OAM
7
Oxford Asset Management
United Kingdom
$19K – – –
PC
8
Periscope Capital
Ontario, Canada
$19K +$1.69K +6,700 +7%
AA
9
AQR Arbitrage
Connecticut
$18K – – –
BCM
10
Bluefin Capital Management
New York
$18K +$25.6K +101,600 New
6CM
11
683 Capital Management
New York
$15K – – –
YCM
12
Yakira Capital Management
Connecticut
$15K – – –
LIM
13
Longfellow Investment Management
Massachusetts
$10K – – –
GCL
14
Glazer Capital LLC
New York
$9K -$244 -967 -2%
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
$5K – – –
Walleye Trading
16
Walleye Trading
New York
$3K +$3.53K +14,000 New
UBS Group
17
UBS Group
Switzerland
$1K – – –
KPF
18
K2 Principal Fund
Ontario, Canada
– -$25.5K -101,200 Closed

NRXPW Hedge Fund Activity: Q1 2019 in Review

17 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals Warrant (NRXPW) for Q1 2019, worth a combined $616K — up 3.9% from $593K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new NRXPW positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Bluefin Capital Management, opening a new position worth an estimated $25.6K. The largest seller was K2 Principal Fund, exiting entirely with an estimated $25.5K sold.

  • 17 institutional investors held NRX Pharmaceuticals Warrant (NRXPW) as of Q1 2019, up from 16 in Q4 2018.
  • Funds reported $616K of NRX Pharmaceuticals Warrant stock for Q1 2019, up 3.9% quarter-over-quarter.
  • 2 funds opened new NRX Pharmaceuticals Warrant positions in Q1 2019 and 1 closed out, a net change of +1 holder.
  • The largest NRX Pharmaceuticals Warrant buyer in Q1 2019 was Bluefin Capital Management, an estimated $25.6K added.
  • The largest NRX Pharmaceuticals Warrant seller in Q1 2019 was K2 Principal Fund, an estimated $25.5K sold.

Based on aggregated 13F filings for Q1 2019.